REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai > Hetero Ring Is Six-membered Consisting Of Two Nitrogens And Four Carbon Atoms (e.g., Pyridazines, Etc.) > 1,4-diazine As One Of The Cyclos > Piperazines (i.e., Fully Hydrogenated 1,4-diazines) > Carbocyclic Ring Bonded Directly To The Piperazine Ring Carbocyclic Ring Bonded Directly To The Piperazine RingCarbocyclic Ring Bonded Directly To The Piperazine Ring patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.01/18/07 - 20070015769 - Use of 5ht4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions The invention relates to the use of a 5-HT4 receptor antagonist in the manufacture of a medicament for the prophylaxis or treatment of atrial remodelling in a mammal. Preferably, the antagonist is N-[(1-nbutyl-4-piperidinyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide (SB 207266) or a pharmaceutically acceptable salt thereof. The invention also relates to the use of SB ... 01/18/07 - 20070015768 - Ubiquitin ligase inhibitors and methods related thereto The application discloses compounds that inhibit ubiquitin ligase activity. The application further discloses antiviral compounds, anticancer compounds, and compounds useful for the treatment of neurological disorders. ... 12/14/06 - 20060281759 - Succinate and malonate salt of trans 4-(ir,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament 4-((1R,3S)-6-Chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine hydrogen succinate or hydrogen malonate, pharmaceutical compositions containing these salts and the medical use thereof, including for the treatment of schizophrenia and other psychotic disorders. Also described are methods for the preparation of 4-((1R,3S)-6-Chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and medical uses thereof. ... 12/14/06 - 20060281758 - Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine A compound 4-((1R,3S)-6-Chloro-3-phenylindan-1-yl)-2,2-dimethylpiperazine and salts thereof, pharmaceutical compositions comprising the compound and salts, and medical use thereof, including for treatment of schizophrenia and other psychotic disorders. ... 12/14/06 - 20060281757 - Phenyl sulfone derivatives and their use in the treatment of cns disorders This invention relates to novel phenyl sulfone compounds having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders. ... 10/05/06 - 20060223830 - Indanyl-piperazine compounds Medical products containing the same which are useful in the treatment of conditions requiring a serotonin reuptake inhibitor and/or NK1 antagonist. ... 09/14/06 - 20060205737 - Substituted arylamine compounds and methods of treatment The invention relates to 5-HT6 receptor antagonists. Novel arylamine compounds and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with serotonin action, such as in treating obesity, and obesity-related disorders, e.g., cardiovascular disease, digestive disease, respiratory disease, cancer and ... 07/27/06 - 20060167014 - Piperazine compounds and medicinal use thereof wherein R1 and R2 are each hydrogen, halogen, lower alkyl, lower alkoxy, amino, substituted amino, nitro, hydroxy or cyano, R3, R4 and R5 are each hydrogen, halogen, lower alkyl, lower alkoxy, nitro, amino, substituted amino or hydroxy, R6 and R7 are each hydrogen, lower alkyl, lower alkyl substituted by halogen, ... 07/27/06 - 20060167013 - Inhibitors for excessive accumulation of sodium ion in cells A medicament for suppressing intracellular excess accumulation of sodium ions and a medicament for therapeutic and/or preventive treatment of cardiac disorders resulting from cardiosurgery operations which comprises an aminobenzenesulfonic acid derivative represented by the following general formula (I) or a salt thereof, or a hydrate thereof or a solvate thereof ... 07/20/06 - 20060160825 - Tetralin and indane derivatives and uses thereof or pharmaceutically acceptable salts thereof, wherein m, p, q, Ar, R1 and R2 are as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formula I. ... 07/06/06 - 20060148821 - N,n-disubstituted diazocycloalkanes (R1=halogen, R2=(C3-C8)-cycloalkyl, R3=(C1-C4)-alkoxy or (C1-C4)-haloalkoxy group, m is 1 or 2 and n is 1 or 2, have affinity for serotonergic receptors. These compounds and their enantiomers, diastereoisomers, N-oxides, polymorphs, solvates and pharmaceutically acceptable salts are useful in the treatment of patients with neuromuscular dysfunction of the lower urinary tract ... 06/08/06 - 20060122193 - 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders Compounds of general formula (1) wherein R1, R2 and R3 are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain. ... 04/27/06 - 20060089368 - Phenyl-piperazine derivatives as serotonin reuptake inhibitors wherein the substituents are defined in the application. The compounds are useful in the treatment of an affective disorder, including depression, anxiety disorders including general anxiety disorder and panic disorder and obsessive compulsive disorder. ... 04/20/06 - 20060084662 - Phenyl-piperazine derivatives as serotonin reuptake inhibitors wherein the substituents are defined in the application. The compounds are useful in the treatment of an affective disorder, including depression, anxiety disorders including general anxiety disorder and panic disorder and obsessive compulsive disorder. ... 01/12/06 - 20060009471 - Amido compounds and their use as pharmaceuticals The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or ... 01/05/06 - 20060004023 - Treatment for attention-deficit hyperactivity disorder A method for treating Attention Deficit/Hyperactivity Disorder (ADHD) in humans and the symptoms associated therewith, inattentiveness, and hyperactivity with impulsivity, using eltoprazine and related compounds is provided. ... 12/29/05 - 20050288304 - Tetrahydronaphthylpiperazines as 5ht1b antagonists, inverse agonists and partial agonists and D is a group of the formula D, wherein Y, W and Z are C or N and wherein R7 is as defined herein and their salts and compositions which include selective antagonists, inverse agonists and partial agonists of serotonin 1 (5-HT1) receptors. Compounds of the invention are useful ... 12/22/05 - 20050282822 - Therapeutic agents The present invention provides a compound of formula I processes for preparing such compounds, their the utility in treating clinical conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance, methods for their therapeutic use and pharmaceutical compositions containing them. ... 12/01/05 - 20050267129 - Dipeptide nitrile cathepsin k inhibitors In which R1 and R2 are independently H or C1-C7lower alkyl, or R1 and R2 together with the carbon atom to which they are attached form a C3-C8cycloalkyl ring, and Het is an optionally substituted nitrogen-containing heterocyclic substituent, are provided, useful e.g. for therapeutic or prophylactic treatment of a disease ... 12/01/05 - 20050267128 - Compounds, compositions and methods of modulating the mitochondrial apoptosis-induced channel (mac) The present invention relates to methods of treating conditions or diseases in which apoptosis is either desirable or undesirable. In particular, in conditions whereby it is desirable to inhibit unwanted cellular proliferation such as in cancers or in hyperproliferative disorders, treatment with an agent that promotes opening of the mitochondrial ... 11/10/05 - 20050250791 - Process for preparing monoarylpiperazines The invention provides a process for preparing arylpiperazines from the corresponding aryl chlorides or bromides and piperazine using a base and a catalyst consisting of a palladium salt and a bisaryldialkylphosphine. ... 10/27/05 - 20050239799 - 1-phenyl-4-benzylpiperazines dopamine receptor subtype R2 and R3 together represent a 4 carbon alkenylene moiety that together with the phenyl ring to which they are attached form a naphthyl moiety, which compounds are useful in the treatment of neuropsycological diseases such as schizophrenia, psychotic depression and mania. ... 06/23/05 - 20050137211 - Phenyl-piperazine derivatives as modulators of muscarinic receptors The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases. ... 06/16/05 - 20050130990 - Nicotinic receptor agonists for the treatment of inflammatory diseases This invention relates to the use of nicotine receptor agonists or analogues or derivatives thereof for treating inflammatory pulmonary diseases. Such agonists have fewer side effects than other anti-inflammatory drugs, such as steroids. Moreover, these agonists can be used alone or in combination with other anti-inflammatory drugs to alleviate pulmonary ... 06/09/05 - 20050124632 - Remedies and/or preventives for diabetic ischemic heart diseases (wherein R1 represents, for example, hydrogen atom; R2 represents, for example, hydrogen atom; and n represents an integer of from 1 to 4) or a salt thereof, or a hydrate thereof or a solvate thereof, and an agent for therapeutic and/or prophylactic treatment of diabetic ischemic heart disease wherein said ... ### FreshPatents.com Support |